Feasibility Study of Ultrasound-guided Functional Remodeling of Lower Extremity Superficial Venous Valve

In this project, an exploratory study was conducted to perform in situ venous valve remodeling in vivo, evaluate venous valve function after surgery and conduct regular follow-up, collect relevant ultrasonic data before, during and after surgery, and evaluate the safety and effectiveness of Ultrasound-guided percutaneous great saphenous vein valve functional remodeling.

Study Overview

Detailed Description

A certain number of patients meeting the requirements (meeting the inclusion criteria, but not meeting the exclusion criteria) were selected for preoperative hemodynamic evaluation of lower extremity vein ultrasound to determine the reflux points and reflux points, identify the blood circulation pattern, and design an individualized surgical program. Intraoperative venous valve was remodeled in situ under ultrasound guidance. Postoperative ultrasound was used to assess venous valve function and complications in the operative area.

Screening period (before surgery 14 days to 0 days) Subject signs informed consent. General information and previous medical history of subjects were collected, preoperative laboratory examination (blood routine, blood biochemistry, coagulation function, preoperative immunity, blood type), electrocardiogram, ultrasound, preoperative hemodynamic evaluation of lower extremity vein were completed, and evaluation scales such as CEAP grading, VCSS, AVVQ, CIVIQ and pain score were completed.

Subjects who meet the inclusion criteria and do not meet all exclusion criteria will be admitted.

Day of surgery (day 0) Preoperative ultrasound was re-evaluated to confirm the valve function, and the tissue was disinfected. Hyaluronic acid was injected around the valve of the great saphenous vein to rebuild the valve about 1-2ml, and the whole process was monitored under ultrasound. During the injection, the valve function was pumped back for protection, and the injection was performed multiple times at different points. Supplementary injection: Following the subject's voluntary principle, the researcher can give supplementary injection after evaluating the general condition of the subject.

The follow-up period for each subject was 12 months ±20 days after enrollment. Follow-up period (±3 days at 1 week, ±5 days at 1 month, ±10 days at 3 months, ±15 days at 6 months, ±20 days at 1 year) General data of subjects were collected, laboratory examination (blood routine and blood biochemistry) and postoperative ultrasound hemodynamic evaluation of lower limb veins were improved, and evaluation scales such as VCSS, AVVQ, CIVIQ and pain score were completed.

This study does not involve vulnerable groups.

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Zhejiang Procince
      • Yiwu, Zhejiang Procince, China, 322000
        • Recruiting
        • The Fourth Affiliated Hospital Zhejiang University School of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 18-80, gender unlimited
  • CEAP grading was C2-C5 patients
  • The patient was clinically diagnosed as a primary varicose great saphenous vein of lower extremity, and the ultrasound findings were great saphenous vein valve insufficiency (complete structure, normal shape, enlarged valve ring, Duration of reflux >0.5s), only unilateral varicose great saphenous vein was treated this time

Exclusion Criteria:

  • Patients with target vessel diameter < 3mm
  • The final valve of the great saphenous vein was not clear or lost its normal shape on ultrasound
  • Patients with deep vein valvular insufficiency
  • The presence of thrombus or thrombophlebitis in the main trunk of great cryptic skin
  • Target diseased blood vessel had previously received surgical treatment
  • Patients with deep vein thrombosis or history of pulmonary distension embolism
  • Patients with active implants such as pacemakers or ICDs
  • Patients with severe abnormal liver and kidney function (more than three times the normal value)
  • Patients with non-primary varicose veins caused by post-deep vein thrombosis syndrome, Cockett syndrome (iliac vein compression syndrome), KT syndrome (venous malformation hypertrophy syndrome >, arteriovenous sputum, etc
  • Any serious or uncontrolled systemic disease (including poorly medicated hypertension, diabetes, and diseases with active bleeding signs or severe coagulopathy)
  • Patients with diseases that may make treatment and evaluation difficult (e.g., malignant arsine tumor, acute infectious diseases, sepsis, systemic intolerability of surgery, life expectancy less than 12 months, etc.)
  • Pregnant and lactating women, or those who planned to have children during the study period
  • Patients who have participated in clinical trials of other drugs or medical devices within the last 3 months
  • Anesthetist and other patients were deemed unsuitable for the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Venous valve remodeling
Venous valve function was remodeled under ultrasound guidance
Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Venous valve regurgitation or not
Time Frame: immediately after intervention
Under the calf compression test, the venous valves were observed for blood flow regurgitation signal
immediately after intervention
Venous valve regurgitation or not
Time Frame: 1 week after intervention
Under the calf compression test, the venous valves were observed for blood flow regurgitation signal
1 week after intervention
Venous valve regurgitation or not
Time Frame: 1 month after intervention
Under the calf compression test, the venous valves were observed for blood flow regurgitation signal
1 month after intervention
Venous valve regurgitation or not
Time Frame: 3 months after intervention
Under the calf compression test, the venous valves were observed for blood flow regurgitation signal
3 months after intervention
Venous valve regurgitation or not
Time Frame: 6 months after intervention
Under the calf compression test, the venous valves were observed for blood flow regurgitation signal
6 months after intervention
Venous valve regurgitation or not
Time Frame: 1 year after intervention
Under the calf compression test, the venous valves were observed for blood flow regurgitation signal
1 year after intervention
Changes in the duration of venous valve regurgitation
Time Frame: immediately after intervention
The duration of venous valve regurgitation was measured under calf compression test
immediately after intervention
Changes in the duration of venous valve regurgitation
Time Frame: 1 week after intervention
The duration of venous valve regurgitation was measured under calf compression test
1 week after intervention
Changes in the duration of venous valve regurgitation
Time Frame: 1 month after intervention
The duration of venous valve regurgitation was measured under calf compression test
1 month after intervention
Changes in the duration of venous valve regurgitation
Time Frame: 3 months after intervention
The duration of venous valve regurgitation was measured under calf compression test
3 months after intervention
Changes in the duration of venous valve regurgitation
Time Frame: 6 months after intervention
The duration of venous valve regurgitation was measured under calf compression test
6 months after intervention
Changes in the duration of venous valve regurgitation
Time Frame: 1 year after intervention
The duration of venous valve regurgitation was measured under calf compression test
1 year after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Yuefeng Zhu, Master's, The Fourth Affiliated Hospital Zhejiang University School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 19, 2023

Primary Completion (Estimated)

December 31, 2023

Study Completion (Estimated)

July 30, 2024

Study Registration Dates

First Submitted

May 24, 2023

First Submitted That Met QC Criteria

June 19, 2023

First Posted (Actual)

June 22, 2023

Study Record Updates

Last Update Posted (Actual)

June 22, 2023

Last Update Submitted That Met QC Criteria

June 19, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Varicose Veins of Lower Limb

3
Subscribe